Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of triamcinolone acetonide and ranibizumab on radiation retinopathy in uveal melanoma
2009-010336-18Phase 3Terminated
- Sponsor
- Maria Antonia Saornil Alvarez
- Start
- Sep 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab and triamcinolone acetonide in Radiation chorioretinopathy and intraocular melanoma (3 arms), sponsored by Maria Antonia Saornil Alvarez. Primary endpoint: Mean change in visual acuity from baseline at 12 months. Started Sep 2009; status: terminated.
02
Drugs
ranibizumabtriamcinolone acetonide
03
Conditions
Radiation chorioretinopathyintraocular melanoma
Beyond the preview
Go deeper on 2009-010336-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010336-18.